Id: acc3241
Group: 2sens
Protein: E2F1
Gene Symbol: E2F1
Protein Id: Q01094
Protein Name: E2F1_HUMAN
PTM: phosphorylation
Site: Ser364
Site Sequence: QEPLLSRMGSLRAPVDEDRLS
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype:
Disease Cellline: MCF-7
Disease Info:
Drug: docetaxel
Drug Info: "Docetaxel is a chemotherapy drug used to treat various types of cancer such as breast, ovarian, and non - small cell lung cancer."
Effect: inhibit
Effect Info: "The oncoprotein CIP2A inhibits PP2A and enhances the phosphorylation of E2F1, forming a positive feedback loop, which ultimately leads to the resistance of breast cancer cells to treatment."
Note:
Score: 5.0
Pubmed(PMID): 23306062
Sentence Index:
Sentence:

Sequence & Structure:

MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
E2F1 EDIFOLIGIDE SODIUM E2F inhibitor 3 Completed coronary artery disease ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
E2F1-Ser364
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: